Evidence map›Paper›PMID 38658392›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Comparison of novel PSMA-targeting [

Linlin Li, Jiarou Wang, Guochang Wang, Rongxi Wang, Wenbin Jin, Jie Zang, Huimin Sui, Chenhao Jia, Yuanyuan Jiang, Haiyan Hong and 5 more

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05603559 (Safety, Dosimetry and Dose-escalation of 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05603559 early_phase1recruitingnot on this map

Safety, Dosimetry and Dose-escalation of 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

TypeinterventionalSponsorPeking Union Medical College HospitalRan2023 to 2026Enrolled30ConditionsMetastatic Castration-resistant Prostate CancerArms1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of 177Lu-P17-088
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Pharmacokinetics and dosimetry of [Annals of nuclear medicine · 2025
    Trial
  2. The Prognostic Value ofAnnals of nuclear medicine · 2026
    Article
  3. Article
  4. Article
  5. Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025
    Article
  6. Safety, pharmacokinetics, and dosimetry ofActa pharmaceutica Sinica. B · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Linlin Li *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Jiarou Wang *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Guochang Wang *Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Rongxi WangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Wenbin JinCollege of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Jie ZangDepartment of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Huimin SuiDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Chenhao JiaDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Yuanyuan JiangDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China.
Haiyan HongCollege of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Lin ZhuCollege of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
David AlexoffFive Eleven Pharma Inc, Philadelphia, PA, 19104, USA.
Karl PloesslFive Eleven Pharma Inc, Philadelphia, PA, 19104, USA.
Hank F KungFive Eleven Pharma Inc, Philadelphia, PA, 19104, USA. kunghf@gmail.com.ORCID 0000-0003-3254-8049
Zhaohui ZhuDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Dongcheng District, Beijing, 100730, China. 13611093752@163.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Normal University · CNFujian Medical University · CNUniversity of Pennsylvania · US

Funding

Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2021-I2M-1-016Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2022-I2M-2-002Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2022-I2M-C&T-A-008the Fundamental Research Funds for the Central Universities 3332022110the National High Level Hospital Clinical Research Funding 2022-PUMCH-C-004the National Natural Science Foundation of China 22176016the National Natural Science Foundation of China 82272046
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [

methodsPatients with PSMA-positive tumors were enrolled after [

resultsPatients showed no major clinical side-effects under this low dose treatment. As expected [

conclusion[

trial registrationCLINICALTRIALS: gov/ct2/show/NCT05603559 .

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IILutetiumNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAlbuminsHumansMaleMiddle AgedRadioisotopesRadiometryRadiopharmaceuticalsAlbuminsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopesRadiopharmaceuticalsLu-177Metastatic castration-resistant prostate cancer (mCRPC)Prostate-specific membrane antigen (PSMA)Radioligand therapy (RLT)

Identifiers

PMID38658392
OpenAlexW4395461047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.